文献速递间质性肺疾病

尼达尼布治疗特发性肺纤维化长期安全性与耐受性:INPULSIS-ON开放标签扩展研究

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
PubMed 文献 · Lancet Respir Med · 2018-09-14

安全性特征与INPULSIS一致,腹泻最常见,无新安全信号,提示长期使用安全可管理。

要点

  • 尼达尼布长期安全性特征与INPULSIS试验一致,无新安全信号。
  • 因IPF进展永久停药最常见,继续组12%,新开始组14%。

核心结论

  • 尼达尼布长期使用安全性及耐受性可管理,无新安全信号,特发性肺纤维化患者可长期使用以延缓疾病进展。

研究设计与样本

  • INPULSIS-ON为开放标签扩展研究,纳入完成52周INPULSIS试验的807例患者中的734例(91%)接受尼达尼布治疗。
  • 430例(59%)在INPULSIS中接受尼达尼布并继续,304例(41%)在INPULSIS中接受安慰剂并开始尼达尼布。
  • 主要结局为至少接受一剂尼达尼布患者的长程安全性与耐受性特征。

主要发现

  • 因腹泻永久停药:继续尼达尼布组20/430例(5%),新开始尼达尼布组31/304例(10%)。
  • 因IPF进展永久停药最常见:继续尼达尼布组51例(12%),新开始尼达尼布组43例(14%)。

临床怎么用

  • 对特发性肺纤维化患者可考虑长期使用尼达尼布以延缓疾病进展,需监测腹泻等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy and safety of nintedanib, an intracellular tyrosine kinase inhibitor, in patients with idiopathic pulmonary fibrosis were assessed in two phase 3, placebo-controlled INPULSIS trials. Patients who completed the 52-week treatment period in an INPULSIS trial could receive open-label nintedanib in the extension trial, INPULSIS-ON. We aimed to assess the long-term efficacy and safety of nintedanib in INPULSIS-ON. METHODS: Patients who completed the 52-week treatment period of INPULSIS, and the follow-up visit 4 weeks later, were eligible for INPULSIS-ON. The off-treatment period between INPULSIS and INPULSIS-ON could be 4-12 weeks. Patients receiving nintedanib 150 mg twice daily or placebo at the end of an INPULSIS trial received nintedanib 150 mg twice daily in INPULSIS-ON. Patients receiving nintedanib 100 mg twice daily or placebo at the end of an INPULSIS trial could receive nintedanib 100 mg twice daily or 150 mg twice daily in INPULSIS-ON. Spirometric tests were done at baseline, at weeks 2, 4, 6, 12, 24, 36, 48, and then every 16 weeks. The primary outcome of INPULSIS-ON was to characterise the long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis, and this was analysed in patients who received at least one dose of nintedanib in INPULSIS-ON. This study is registered with ClinicalTrials.gov, number NCT01619085, and with EudraCT, number 2011-002766-21. FINDINGS: The first patient was enrolled into INPULSIS-ON in July 2, 2012. Of 807 patients who completed the INPULSIS trials, 734 (91%) were treated in INPULSIS-ON. 430 (59%) patients had received nintedanib in INPULSIS and continued nintedanib in INPULSIS-ON, and 304 (41%) had received placebo in INPULSIS and initiated nintedanib in INPULSIS-ON. Median exposure time for patients treated with nintedanib in both the INPULSIS and INPULSIS-ON trials was 44·7 months (range 11·9-68·3). The safety profile of nintedanib in INPULSIS-ON was consistent with that observed in INPULSIS. Diarrhoea was the most frequent adverse event in INPULSIS-ON (60·1 events per 100 patient exposure-years in patients who continued nintedanib, 71·2 events per 100 patient exposure-years in patients who initiated nintedanib). 20 (5%) of 430 patients who continued nintedanib and 31 (10%) of 304 patients who initiated nintedanib permanently discontinued nintedanib because of diarrhoea. The adverse event that most frequently led to permanent discontinuation of nintedanib was progression of idiopathic pulmonary fibrosis (51 [12%] patients continuing nintedanib and 43 [14%] patients initiating nintedanib). The event rate of bleeding was 8·4 events per 100 patient exposure-years in patients who continued nintedanib and 6·7 events per 100 patient exposure-years in patients who initiated nintedanib. The event rate of major adverse cardiovascular events was 3·6 events per 100 patient exposure-years in patients who continued nintedanib and 2·4 events per 100 patient exposure-years in patients who initiated nintedanib. The event rate of myocardial infarction using the broad scope (ie, all possible cases) was 1·3 events per 100 patient exposure-years in patients who continued nintedanib and 0·7 events per 100 patient exposure-years in patients who initiated nintedanib. INTERPRETATION: These findings suggest that nintedanib has a manageable safety and tolerability profile over long-term use, with no new safety signals. Patients with idiopathic pulmonary fibrosis could use nintedanib over the long-term to slow disease progression. FUNDING: Boehringer Ingelheim.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2018. PMID: 30224318. doi:10.1016/S2213-2600(18)30339-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。